A Potential Pneumothorax Induced by Immune Checkpoint Inhibitors: A Case Report and Literature Review

• Published in: Medicina (Kaunas, Lithuania) Lithuania), 2024-10, Vol.60 (10), p.1634
• Main Authors: Shin, Yoon-E, Kim, Hyuk, Yoo, Jeong-Ju, Kim, Sang Gyune, Kim, Young Seok
• Format: Article
• Language: English
• Subjects: Aged; Antibodies; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; atezolizumab; Cancer; Cancer therapies; Carcinoma, Hepatocellular - drug therapy; Case Report; Chemoembolization; Chemotherapy; Chronic obstructive pulmonary disease; Complications and side effects; Diagnosis; Drug therapy; Emphysema; Hepatoma; Humans; immune checkpoint inhibitor; Immune Checkpoint Inhibitors - adverse effects; immune-related adverse events; Immunotherapy; Literature reviews; Liver cancer; Liver Neoplasms - drug therapy; Lungs; Lymphocytes; Male; Methods; Ostomy; Pneumothorax; Pneumothorax - chemically induced; Radiation therapy; Risk factors; Side effects
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina60101634

Immune checkpoint inhibitors (ICIs), which target immune checkpoints in cancer cells, are increasingly used as a mainstay in anticancer treatment. The combination of atezolizumab and bevacizumab is also a first-line treatment for hepatocellular carcinoma (HCC). However, ICIs can cause immune-related adverse events (IrAEs) which range from mild to severe, potentially leading to the need for discontinuing immunotherapy. We report a case of a pneumothorax, a rare side effect caused by IrAEs. This paper reports a case of a 78-year-old male HCC patient who developed a recurrent pneumothorax, suspected to be an adverse effect of ICIs. The patient was a current smoker with a 30 pack-year smoking history. Prior to initiating ICIs, a chest CT scan showed mild emphysema and fibrosis attributable to smoking. Following ICI treatment, the patient developed a recurrent pneumothorax. Further tests revealed no underlying cause for the pneumothorax other than the ICIs and smoking, and there were no signs of intrapulmonary metastasis or pneumonitis. When a pneumothorax occurs in a patient undergoing immunotherapy, it is important to consider it as a potential adverse effect of the treatment. Special attention should be given to the possibility that immunotherapy may exacerbate underlying lung conditions. Patients should be advised on the importance of smoking cessation. As there are currently no guidelines for resuming immunotherapy after a pneumothorax, it is crucial to weigh the risks and benefits and consider dose reduction or discontinuation of the medication.